What is the share price of Asarfi Hospital Ltd (ASARFI) today?
The share price of ASARFI as on 27th July 2026 is ₹213.75. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Asarfi Hospital Ltd (ASARFI) share?
The past returns of Asarfi Hospital Ltd (ASARFI) share are- Past 1 week: -1.02%
- Past 1 month: -7.07%
- Past 3 months: -4.23%
- Past 6 months: 31.58%
- Past 1 year: 64.42%
- Past 3 years: 96.24%
- Past 5 years: 106.04%
What are the peers or stocks similar to Asarfi Hospital Ltd (ASARFI)?
The peers or stocks similar to Asarfi Hospital Ltd (ASARFI) include:What is the market cap of Asarfi Hospital Ltd (ASARFI) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Asarfi Hospital Ltd (ASARFI) is ₹420.60 Cr as of 27th July 2026.What is the 52 week high and low of Asarfi Hospital Ltd (ASARFI) share?
The 52-week high of Asarfi Hospital Ltd (ASARFI) is ₹256.95 and the 52-week low is ₹117.20.What is the PE and PB ratio of Asarfi Hospital Ltd (ASARFI) stock?
The P/E (price-to-earnings) ratio of Asarfi Hospital Ltd (ASARFI) is 25.25. The P/B (price-to-book) ratio is 5.19.Which sector does Asarfi Hospital Ltd (ASARFI) belong to?
Asarfi Hospital Ltd (ASARFI) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Asarfi Hospital Ltd (ASARFI) shares?
You can directly buy Asarfi Hospital Ltd (ASARFI) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Asarfi Hospital Ltd
ASARFI Share Price
BSE₹213.750.33% (+0.70)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ASARFI Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
ASARFI Performance & Key Metrics
ASARFI Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 25.26 | 5.19 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.27 | 5.97 | 0.52% |
ASARFI Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
ASARFI Company Profile
Asarfi Hospital Limited is an integrated healthcare service provider in India, operating a 250-bedded multi-specialty hospital. It offers comprehensive healthcare services, including prevention, treatment, and rehabilitation across various medical departments such as cardiology, surgery, and pediatrics.
APOLLOHOSP
PE Ratio
65.49
65.49
1Y Return
20.21%
20.21%
Buy Reco %
86.67
86.67
MAXHEALTH
PE Ratio
75.21
75.21
1Y Return
11.36%
11.36%
Buy Reco %
83.33
83.33
FORTIS
PE Ratio
68.29
68.29
1Y Return
11.35%
11.35%
Buy Reco %
85.00
85.00
ASTERDM
PE Ratio
180.00
180.00
1Y Return
39.06%
39.06%
Buy Reco %
100.00
100.00
PE Ratio
51.78
51.78
1Y Return
3.15%
3.15%
Buy Reco %
85.71
85.71
ASARFI Sentiment Analysis
ASARFI Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ASARFI Stock Summary · May 2026
Management framed the call around strong FY26 growth and confident near‑term targets, reporting consolidated revenue up 42% to INR 173.5 crore and consolidated EBITDA rising 42% to INR 35.3 crore (20% margin). Leadership emphasized scaling clinical capacity and margin improvement as priorities — expanding cardiology beds from 25 to 45, commissioning a Philips Azurion cath lab, raising ARPOB to INR 23,000, growing surgeries 26% to over 6,300 and expanding regional outpatient reach — alongside a planned increase in cancer capacity from 65 to 150 beds and an M&A that is substantially agreed. They acknowledged constraints, including delayed bone‑marrow transplant approvals that push meaningful revenue into FY28, pressure on cash realization from government cashless schemes with elevated receivables aged six to seven months, and modest near‑term capex (under INR 15 crore) funded largely from internal accruals. Management reiterated FY27 targets of INR 260 crore revenue, a PAT mix of 13%–15%, and at least a 22% EBITDA margin as they pursue case‑mix, geographic expansion and cost measures.
ASARFI Stock Growth Drivers
ASARFI Stock Growth Drivers
6Enhanced corporate governance, transparency and investor engagement
The company has taken deliberate steps to strengthen governance and investor communication by voluntarily adopting
Robust FY26 operational and financial performance
FY26 delivered marked, broad‑based improvement with consolidated revenue up 42% year‑on‑year to INR 173.5 crore
ASARFI Stock Challenges
ASARFI Stock Challenges
5Regulatory and administrative approval delays disrupting operations
The company has experienced multiple regulatory and administrative setbacks that have already delayed operations and
Reimbursement pressure and strained cash realization from government schemes
Government cashless‑treatment schemes are exerting sustained pressure on cash realization and revenue sustainability. Management reported
ASARFI Forecast
ASARFI Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
ASARFI
ASARFI
Income
Balance Sheet
Cash Flow
Quarterly Normal View
ASARFI Income Statement
ASARFI Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 21.25 | 23.63 | 23.60 | 31.99 | 33.78 | 38.71 | 37.10 | 45.65 | 47.57 | 45.89 | ||||||||||
Operating & Other expenses | 16.04 | 20.09 | 18.16 | 24.10 | 25.94 | 28.82 | 28.69 | 36.02 | 35.99 | 37.52 | ||||||||||
EBITDA | 5.21 | 3.54 | 5.44 | 7.89 | 7.84 | 9.89 | 8.41 | 9.63 | 11.58 | 8.37 | ||||||||||
| Depreciation/Amortization | 3.25 | 3.49 | 3.18 | 3.19 | 3.05 | 3.25 | 2.99 | 2.91 | 2.88 | 2.76 | ||||||||||
| PBIT | 1.96 | 0.05 | 2.26 | 4.70 | 4.79 | 6.64 | 5.42 | 6.72 | 8.70 | 5.61 | ||||||||||
| Interest & Other Items | 0.60 | 0.76 | 0.80 | 0.76 | 1.18 | 1.35 | 1.22 | 1.07 | 1.25 | 0.71 | ||||||||||
| PBT | 1.36 | -0.71 | 1.46 | 3.94 | 3.61 | 5.29 | 4.20 | 5.65 | 7.45 | 4.90 | ||||||||||
| Taxes & Other Items | 1.40 | -0.51 | 0.00 | 1.08 | 0.93 | 1.71 | 1.08 | 1.45 | 2.03 | 0.99 | ||||||||||
| Net Income | -0.04 | -0.20 | 1.46 | 2.86 | 2.68 | 3.58 | 3.12 | 4.20 | 5.42 | 3.91 | ||||||||||
| EPS | -0.03 | -0.18 | 0.74 | 1.45 | 1.36 | 1.82 | 1.59 | 2.13 | 2.76 | 1.99 |
ASARFI Company Updates
ASARFI Stock Peers
ASARFI Past Performance & Peer Comparison
ASARFI Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHospitals & Diagnostic Centres
Compare valuation on Screener
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Asarfi Hospital Ltd | 25.25 | 5.19 | — |
| Apollo Hospitals Enterprise Ltd | 65.49 | 11.46 | 0.23% |
| Max Healthcare Institute Ltd | 75.21 | 10.09 | 0.18% |
| Fortis Healthcare Ltd | 68.29 | 7.00 | 0.11% |
ASARFI Stock Price Comparison
Compare ASARFI with any stock or ETFCompare ASARFI with any stock or ETF
ASARFI
ASARFI Holdings
ASARFI Shareholdings
ASARFI Promoter Holdings Trend
ASARFI Promoter Holdings Trend
ASARFI Institutional Holdings Trend
ASARFI Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ASARFI Shareholding Pattern
ASARFI Shareholding Pattern
ASARFI Shareholding History
ASARFI Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ASARFI stock
smallcases containing ASARFI stock
Looks like this stock is not in any smallcase yet.
ASARFI Events
ASARFI Events
ASARFI Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ASARFI has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ASARFI Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ASARFI has not given any dividends in last 5 years
ASARFI Dividends
ASARFI Dividends
Hmm, looks like data is unavailable here. Please come back after some timeASARFI Stock News & Opinions
ASARFI Stock News & Opinions
Articles & Videos
Earnings
Earnings
Asarfi Hospital consolidated net profit rises 9.19% in the March 2026 quarterNet profit of Asarfi Hospital rose 9.19% to Rs 3.92 crore in the quarter ended March 2026 as against Rs 3.59 crore during the previous quarter ended March 2025. Sales rose 28.89% to Rs 45.24 crore in the quarter ended March 2026 as against Rs 35.10 crore during the previous quarter ended March 2025. For the full year,net profit rose 57.47% to Rs 16.66 crore in the year ended March 2026 as against Rs 10.58 crore during the previous year ended March 2025. Sales rose 42.47% to Rs 173.50 crore in the year ended March 2026 as against Rs 121.78 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales45.2435.10 29 173.50121.78 42 OPM %17.0617.89 -20.3320.33 - PBDT7.668.55 -10 33.7426.99 25 PBT4.905.30 -8 22.1914.31 55 NP3.923.59 9 16.6610.58 57 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Asarfi Hospital to table resultsAsarfi Hospital will hold a meeting of the Board of Directors of the Company on 11 May 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Asarfi Hospital consolidated net profit rises 102.24% in the December 2025 quarterNet profit of Asarfi Hospital rose 102.24% to Rs 5.42 crore in the quarter ended December 2025 as against Rs 2.68 crore during the previous quarter ended December 2024. Sales rose 40.16% to Rs 46.10 crore in the quarter ended December 2025 as against Rs 32.89 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales46.1032.89 40 OPM %21.9121.16 - PBDT10.336.67 55 PBT7.453.62 106 NP5.422.68 102 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Asarfi Hospital to discuss resultsAsarfi Hospital will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Earnings
Asarfi Hospital consolidated net profit rises 47.37% in the September 2025 quarterNet profit of Asarfi Hospital rose 47.37% to Rs 4.20 crore in the quarter ended September 2025 as against Rs 2.85 crore during the previous quarter ended September 2024. Sales rose 45.46% to Rs 44.89 crore in the quarter ended September 2025 as against Rs 30.86 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales44.8930.86 45 OPM %19.7621.91 - PBDT8.567.13 20 PBT5.653.94 43 NP4.202.85 47 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Asarfi Hospital to hold AGMAsarfi Hospital announced that the 20th Annual General Meeting(AGM) of the company will be held on 12 September 2025.Powered by Capital Market - Live
11 months agoCapital Market - Live
Corporate
Corporate
Asarfi Hospital to convene board meetingAsarfi Hospital will hold a meeting of the Board of Directors of the Company on 20 August 2025.Powered by Capital Market - Live
11 months agoCapital Market - Live
Earnings
Earnings
Asarfi Hospital consolidated net profit rises 115.17% in the June 2025 quarterNet profit of Asarfi Hospital rose 115.17% to Rs 3.12 crore in the quarter ended June 2025 as against Rs 1.45 crore during the previous quarter ended June 2024. Sales rose 55.67% to Rs 35.68 crore in the quarter ended June 2025 as against Rs 22.92 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales35.6822.92 56 OPM %19.5920.72 - PBDT7.194.64 55 PBT4.201.45 190 NP3.121.45 115 Powered by Capital Market - Live
11 months agoCapital Market - Live
Corporate
Corporate
Asarfi Hospital announces board meeting dateAsarfi Hospital will hold a meeting of the Board of Directors of the Company on 7 August 2025.Powered by Capital Market - Live
11 months agoCapital Market - Live
Earnings
Earnings
Asarfi Hospital reports consolidated net profit of Rs 3.59 crore in the March 2025 quarterNet profit of Asarfi Hospital reported to Rs 3.59 crore in the quarter ended March 2025 as against net loss of Rs 0.21 crore during the previous quarter ended March 2024. Sales rose 40.97% to Rs 33.89 crore in the quarter ended March 2025 as against Rs 24.04 crore during the previous quarter ended March 2024. For the full year,net profit rose 154.33% to Rs 10.58 crore in the year ended March 2025 as against Rs 4.16 crore during the previous year ended March 2024. Sales rose 42.86% to Rs 120.57 crore in the year ended March 2025 as against Rs 84.40 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales33.8924.04 41 120.5784.40 43 OPM %14.9616.43 -19.5319.02 - PBDT8.552.77 209 26.9915.03 80 PBT5.30-0.72 LP 14.316.24 129 NP3.59-0.21 LP 10.584.16 154 Powered by Capital Market - Live
1 year agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant